Opinion|Videos|June 26, 2024
Biologic Options in Pediatric Asthma
The panel discusses the biologic drugs approved for use in children with asthma, including omalizumab, dupilumab, mepolizumab, and the recently approved benralizumab. They share their preferences among these options for improving lung function in pediatric patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5